Results S1: Derivation of Inputs into Mech KiM model for Pitavastatin
In the kidney, pitavastatin is a substrate of OAT3 with Km = 3.3 µM (Fujino et al., 2005) . To obtain Jmax, CLint from experiments conducted in kidney slices were used (Watanabe et al., 2011 ). where Papp,trans,n,I represents apparent permeability contributed by the n th transporter in the i th segment of the intestine, A represents the transwell surface area, fuinc represents the fraction unbound in the incubation system, Clumen,i represents the concentration of substrate in the lumen of the i th segment.
From experiments conducted on Caco-2 cells (Ölander et al., 2016) : (Fischer et al., 1999 ): At pH = 6.8
Time (h) 0.25 0.5 0.75 1 % Dissolved 100 100 100 100 Dissolution data of Crestor ® 10 mg (pH = 8.6) and 40 mg (pH = 1.2) were used (Farshi, 2011; Potur, 2014) . Bi et al. (2013) and Vildhede et al. (2015) Tab. S14: Tissue concentration of radioactivity and tissue-to-plasma equilibrium distribution ratio (Kp) for rosuvastatin Tissue concentration of radioactivity (ng.eq/g or ng.eq/ml) and Kp after single oral administration of 14 C-rosuvastatin at 5 mg/kg in male Sprague-Dawley rats at various time points (Nezasa et al., 2002 C-pitavastatin at 1 mg/kg in male SpragueDawley rats at various time points (Kimata et al., 1998) . n.d., not detected Values in bold represent the largest Kp value observed and are used in our model.
Tab. S16: Tissue concentration of total radioactivity and Kp for pitavastatin
Tissue concentration of radioactivity (ng.eq/g or ng.eq/ml) and Kp after single oral administration of 14 C-pitavastatin at 1 mg/kg in male Sprague-Dawley rats at various time points (Kimata et al., 1998 
